Cargando…
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells
Lysine-Specific Demethylase 1 (LSD1) over-expression correlates with poorly differentiated neuroblastoma and predicts poor outcome despite multimodal therapy. We have studied the efficacy of reversible and specific LSD1 inhibition with HCI-2509 in neuroblastoma cell lines and particularly the effect...
Autores principales: | Gupta, Sumati, Doyle, Kelly, Mosbruger, Timothy L., Butterfield, Andrew, Weston, Alexis, Ast, Allison, Kaadige, Mohan, Verma, Anupam, Sharma, Sunil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839410/ https://www.ncbi.nlm.nih.gov/pubmed/29515779 http://dx.doi.org/10.18632/oncotarget.24035 |
Ejemplares similares
-
Antiviral Properties of the LSD1 Inhibitor SP-2509
por: Harancher, Mitchell R., et al.
Publicado: (2020) -
Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas
por: Petrov, Ivan, et al.
Publicado: (2017) -
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
por: Gupta, S, et al.
Publicado: (2016) -
Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation
por: Pishas, Kathleen I., et al.
Publicado: (2018) -
The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma
por: García-Domínguez, Daniel Jose, et al.
Publicado: (2018)